Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $180.2652W HIGH $284.05
Volume
651.15 K
Value Traded
375.98 M
Short % Float
10.2%
+3.58%Week
+3.08%1 Month
+11.21%3 Month
-0.94%6 Month
+2.99%5 Year
+27,640%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
32.71 B
EPS (TTM)
10.56
P/E Ratio
21.47
Ent. Value
31.90 B
Total Shares
144.25 M
Float Shares
139.27 M
Insiders
0.97%
Institutions
74.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RMD Catalyst Timeline
Dated clinical, regulatory and corporate events for ResMed Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ResMed Inc.
194Total events
7Upcoming
30Tier-1 (high impact)
2018 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
ResMed announces collaboration with 23XI Racing and Tyler Reddick
◆AcquisitionCorporate
ResMed enters definitive agreement to sell MatrixCare business to Frazier Healthcare Partners
◆Oral PresentationPresentation
ResMed to present at 46th Annual William Blair Growth Stock Conference
▲Product LaunchPost-Market
Launched AirTouch F30i Comfort full face mask in the U.S.
Sleep apneasource ↗
◆Oral PresentationPresentation
ResMed presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Product LaunchPost-Market
Limited U.S. beta launch for new myAir users
obstructive sleep apneasource ↗
▲Partnership / LicenseCorporate
Partnered with ŌURA to expand access to sleep health education
▲FDA Filing AcceptedRegulatory Filing
FDA clearance for Personalized Therapy Comfort Settings (Smart Comfort)
obstructive sleep apneasource ↗
◆Oral PresentationPresentation
ResMed presents at Bank of America Global Healthcare Conference 2025
▲Poster PresentationPresentation
AirTouch N30i wins Red Dot Awards: Product Design 2025 in Innovative Products and Medical Design & Healthcare categories
obstructive sleep apneasource ↗
▲Patent GrantedIP / Competition
ResMed reaches 10,000 patents and designs (granted or pending)
▲Quarterly UpdateCorporate
Board declares quarterly dividend of $0.60 per share, a 13% increase
◆AcquisitionCorporate
ResMed announces acquisition of VirtuOx, an independent diagnostic testing facility
▲Product LaunchNightOwlApprovedPost-Market
NightOwl home sleep apnea test now available across the United States
obstructive sleep apneasource ↗
▲PublicationPresentation
Meta-analysis in The Lancet Respiratory Medicine showing CPAP reduces death risk in OSA
obstructive sleep apneasource ↗
▲FDA ApprovalNightOwlApprovedFDA Decision
FDA clearance of NightOwl home sleep apnea test
obstructive sleep apneasource ↗
▲Product LaunchNightOwlApprovedPost-Market
NightOwl now available across the United States
obstructive sleep apneasource ↗
◆Oral PresentationPresentation
ResMed presents at 43rd Annual J.P. Morgan Healthcare Conference
◆Management ChangeCorporate
Christopher DelOrefice to stand for re-election at annual meeting
◆Oral PresentationPresentation
ResMed participates in UBS Global Healthcare Conference fireside chat
Past FDA Catalysts and PDUFA Decisions
How RMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
3
Drugs Scored
-
rNPV / MCap
Top 64%
Mid Cap(rank 421 of 658)
Percentile Rank
ResMed Inc. faces pipeline headwinds (32/100), with 3 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every RMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Farrell Michael J.Director, Officer (Chairman and CEO) | Option | 4,991 484,794 held | $146.34 | 10/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.7 % (16.7 %) | 6.43 M | 32.98 K | 45.8% ( 10.36 K) |
RMD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RMD ranks across every disease it competes in
Competitive Position is a premium feature
See how RMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRMD News
RMDResmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
Resmed has announced it will release its financial results for the first quarter of fiscal year 2027 on October 29, 2026. Following the release, a webcast will be held to discuss the results and other relevant information. The earnings call will be accessible via a dedicated webcast link, with replays available afterward.
Read more →RMDResmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
Resmed announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference, scheduled for September 15, 2026. CEO Mick Farrell and CFO Aaron Bloomer will represent the company, presenting via a webcast starting at 10:00 a.m. ET. The event highlights Resmed's commitment to innovative health technologies.
Read more →RMD23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
Resmed has partnered with NASCAR driver Tyler Reddick to raise awareness about sleep apnea following his diagnosis. Reddick's experience highlights the importance of recognizing symptoms and seeking treatment, as he achieved remarkable success after starting CPAP therapy. The initiative aims to educate others on the impact of sleep health on performance and overall well-being.
Read more →RMDResmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
Resmed has announced the appointment of Carol Burt as Lead Director, effective November 15, 2026, succeeding Ron Taylor, who will retire after over 21 years on the Board. Burt, a Board member since 2013, brings significant governance experience. The transition is seen as a strategic move to enhance Resmed's leadership as it continues to grow.
Read more →RMD▼ -5.1%on this news
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
Resmed Inc. reported strong financial results for Q4 FY2026, with revenue increasing by 9% to a record $1.5 billion. The company also saw a 16% rise in non-GAAP diluted earnings per share. Resmed returned over $1 billion to shareholders and announced plans for further investment in innovation and digital capabilities. The company continues to expand its product offerings and market presence.
Read more →RMDCleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges
Cleveland Medical Devices Inc. reported positive outcomes in five of six inter partes review petitions against ResMed at the PTAB. The board found that ResMed failed to prove that the challenged patent claims were unpatentable in four cases, while one case was denied institution. However, ResMed did secure a favorable decision in one proceeding. Ongoing litigation regarding infringement remains pending.
Read more →RMD▼ -6.3%on this newsshared move
Resmed Announces Agreement to Sell MatrixCare Business
Resmed has announced a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners. This decision aligns with Resmed's 2030 strategy to concentrate on scalable opportunities in sleep and breathing health. The transaction is expected to close in the first quarter of fiscal year 2027, pending regulatory approvals. Resmed aims to enhance its focus on innovation and operational scale.
Read more →RMDResmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
Resmed has announced that it will release its financial results for the fourth quarter of fiscal year 2026 on August 6, 2026. Following the release, management will host a webcast to discuss the results and other material information. The webcast will be accessible via their investor relations website.
Read more →RMDResmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Resmed has completed its acquisition of Noctrix Health, enhancing its clinical sleep health offerings. This acquisition includes the Nidra® Tonic Motor Activation (TOMAC) Therapy, a non-invasive treatment for moderate-to-severe Restless Legs Syndrome (RLS). The integration of Noctrix's technology aims to improve patient access and outcomes in sleep health. Resmed's CEO expressed optimism about scaling solutions to enhance lives through better sleep.
Read more →RMDResmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
Resmed has partnered with Oura to improve access to sleep health education and care. This collaboration aims to leverage wearable technology to help users better understand their sleep patterns and connect with healthcare resources. With a significant portion of sleep disorders going undiagnosed, the partnership seeks to raise awareness and facilitate informed discussions between users and healthcare providers.
Read more →RMDResmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
Resmed has announced its participation in the 46th Annual William Blair Growth Stock Conference, scheduled for June 2, 2026. CEO Mick Farrell and CFO Aaron Bloomer will represent the company, with a webcast presentation set to begin at 4:40 p.m. Central Time. The event emphasizes Resmed's focus on innovative health technologies.
Read more →RMDResmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
Resmed announced the retirement of Chief Financial Officer Brett Sandercock, effective May 4, 2026, after 27 years at the company, including 20 as CFO. Aaron Bloomer, formerly CFO at Exact Sciences, has been appointed as Sandercock's successor. The transition is seen as positive, with expectations that Bloomer will effectively drive growth and support Resmed's vision for enhanced digital health solutions. Sandercock will continue to serve as an advisor through the end of 2027.
Read more →RMDResmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
Resmed announced the retirement of CFO Brett Sandercock, effective May 4, 2026, after 27 years with the company. Aaron Bloomer, previously CFO at Exact Sciences, has been appointed as his successor. The leadership transition aims to support Resmed's 2030 strategy and continued growth in health technology. Sandercock will remain as an advisor until the end of 2027.
Read more →RMDResmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Resmed Inc. reported strong financial results for Q3 FY 2026, with an 11% revenue increase to $1.4 billion. The company achieved significant gross margin expansion and a notable rise in earnings per share. CEO Mick Farrell highlighted the ongoing demand for their products and the strategic focus on enhancing digital health capabilities. Resmed also announced a new distribution center to bolster U.S. operations.
Read more →RMDResmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
Resmed has announced the release date for its third quarter fiscal 2026 earnings, scheduled for April 30, 2026, after market close. Following the earnings report, management will host a webcast to discuss the results and other relevant information. The webcast will be accessible via a specific link, and replays will be available for a limited time.
Read more →RMDResmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
Resmed's Global Sleep Survey reveals that while 53% of respondents consider sleep crucial for health, many struggle to achieve quality rest. The survey, conducted with 30,000 participants across 13 countries, highlights a gap between awareness and action, with only 23% seeking medical help for sleep issues. Increased use of wearables for sleep tracking indicates growing awareness, yet barriers remain in addressing sleep health effectively.
Read more →RMDResmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana
Resmed is set to open a new distribution center in Greenwood, Indiana, in 2027, enhancing its U.S. operations. This facility will serve as a logistics hub, improving delivery efficiency across North America and creating over 100 jobs. The center aims to strengthen Resmed's commitment to the local community while enhancing service to patients and providers.
Read more →RMDResmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
Resmed Inc. reported strong second quarter results for fiscal year 2026, showcasing an 11% increase in revenue and a significant expansion in gross margins. The company continues to experience robust demand for its sleep and respiratory care devices, alongside growth in its digital health ecosystem. Resmed plans to invest further in innovation to enhance global access to healthcare.
Read more →About ResMed Inc.
Headquarters9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
BIOPHARMAWATCH ELITE PLUS
Trade the next RMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime